[Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
BACKGROUND
Secondary myelodysplasia after antimitotic therapy is a rare complication usually observed with alkylating agents. The condition usually progresses to acute leukaemia with very poor short term prognosis.


METHODS
We report the cases of 2 women who developed myelodysplasia 2 and 9 months after treatment associating dacarbazine and fotemustine for visceral metastases of a malignant melanoma.


CONCLUSIONS
The frequency of these rare complications is probably underestimated because of the rapid unfavourable outcome of metastatic malignant melanoma. We were unable to determine whether dacarbazine, fotemustine or their combination was incriminated in this complication. Risk could be reduced by carefully determining the cumulative doses of these antimitotics.
Perrot
J L
JL
Service de Dermatologie, CHU Saint-Etienne.
Lanthier
K
K
Benoit
F
F
Graille
M C
MC
Guy
C
C
Bertheas
M F
MF
Cambazard
F
F
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000556:secondary; D003606:Dacarbazine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D009607:Nitrosourea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D003606:Dacarbazine; C054368:fotemustine
Syndromes myélodysplasiques acquis après traitement par fotémustine et dacarbazine pour mélanome.